PYXS Quote, Financials, Valuation and Earnings

Ironwood Pharmaceuticals, Inc. has a net margin of -650.85% compared to Pyxis Oncology, Inc.'s net margin of 32.84%. Pyxis Oncology, Inc.'s return on equity of -90.91% beat Ironwood Pharmaceuticals, Inc.'s return on equity of --.

Pyxis Oncology, Inc. has a consensus price target of $7.18, signalling upside risk potential of 307.67%. On the other hand Ironwood Pharmaceuticals, Inc. has an analysts' consensus of $3.17 which suggests that it could fall by -22%. Given that Pyxis Oncology, Inc. has higher upside potential than Ironwood Pharmaceuticals, Inc., analysts believe Pyxis Oncology, Inc. is more attractive than Ironwood Pharmaceuticals, Inc..

Pyxis Oncology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ironwood Pharmaceuticals, Inc. has a beta of 0.185, suggesting its less volatile than the S&P 500 by 81.483%.

Pyxis Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ironwood Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pyxis Oncology, Inc. pays -- of its earnings as a dividend. Ironwood Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Pyxis Oncology, Inc. quarterly revenues are --, which are smaller than Ironwood Pharmaceuticals, Inc. quarterly revenues of $122.1M. Pyxis Oncology, Inc.'s net income of -$22M is lower than Ironwood Pharmaceuticals, Inc.'s net income of $40.1M. Notably, Pyxis Oncology, Inc.'s price-to-earnings ratio is -- while Ironwood Pharmaceuticals, Inc.'s PE ratio is 26.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pyxis Oncology, Inc. is 38.24x versus 2.02x for Ironwood Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -650.85% compared to Pyxis Oncology, Inc.'s net margin of 21.32%. Pyxis Oncology, Inc.'s return on equity of -90.91% beat Pfizer Inc.'s return on equity of 10.84%.

Pyxis Oncology, Inc. has a consensus price target of $7.18, signalling upside risk potential of 307.67%. On the other hand Pfizer Inc. has an analysts' consensus of $28.66 which suggests that it could grow by 12.47%. Given that Pyxis Oncology, Inc. has higher upside potential than Pfizer Inc., analysts believe Pyxis Oncology, Inc. is more attractive than Pfizer Inc..

Pyxis Oncology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.

Pyxis Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.75% to investors and pays a quarterly dividend of $0.43 per share. Pyxis Oncology, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Pyxis Oncology, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Pyxis Oncology, Inc.'s net income of -$22M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Pyxis Oncology, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pyxis Oncology, Inc. is 38.24x versus 2.32x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -650.85% compared to Pyxis Oncology, Inc.'s net margin of -316.61%. Pyxis Oncology, Inc.'s return on equity of -90.91% beat Plus Therapeutics, Inc.'s return on equity of --.

Pyxis Oncology, Inc. has a consensus price target of $7.18, signalling upside risk potential of 307.67%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $7.16 which suggests that it could grow by 1189.18%. Given that Plus Therapeutics, Inc. has higher upside potential than Pyxis Oncology, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Pyxis Oncology, Inc..

Pyxis Oncology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.845, suggesting its less volatile than the S&P 500 by 15.456%.

Pyxis Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pyxis Oncology, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Pyxis Oncology, Inc. quarterly revenues are --, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Pyxis Oncology, Inc.'s net income of -$22M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Pyxis Oncology, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pyxis Oncology, Inc. is 38.24x versus 8.90x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -650.85% compared to Pyxis Oncology, Inc.'s net margin of 3.93%. Pyxis Oncology, Inc.'s return on equity of -90.91% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Pyxis Oncology, Inc. has a consensus price target of $7.18, signalling upside risk potential of 307.67%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 119.94%. Given that Pyxis Oncology, Inc. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Pyxis Oncology, Inc. is more attractive than Xtant Medical Holdings, Inc..

Pyxis Oncology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.077, suggesting its less volatile than the S&P 500 by 107.701%.

Pyxis Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pyxis Oncology, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Pyxis Oncology, Inc. quarterly revenues are --, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Pyxis Oncology, Inc.'s net income of -$22M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Pyxis Oncology, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 66.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pyxis Oncology, Inc. is 38.24x versus 0.74x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.